The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies

被引:93
作者
Mitsiades, Constantine S. [1 ]
McMillin, Douglas W. [1 ]
Klippel, Steffen [1 ]
Hideshima, Teru [1 ]
Chauhan, Dharminder [1 ]
Richardson, Paul G. [1 ]
Munshi, Nilchil C. [1 ]
Anderson, Kenneth C. [1 ]
机构
[1] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA
关键词
D O I
10.1016/j.hoc.2007.08.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Multiple myeloma (MM) is viewed as a prototypic disease state for the study of how neoplastic cells interact with their local bone marrow (BM) microenvironment. This interaction reflects not only the osteotropic clinical behavior of MM and the clinical impact of the lytic bone lesions caused by its tumor cells but also underlines the broadly accepted notion that nonneoplastic cells of the BM can attenuate the activity of cytotoxic chemotherapy and glucocorticoids. This article summarizes the recent progress in characterization, at the molecular and cellular levels, of how the BM milieu interacts with MM cells and modifies their biologic behavior.
引用
收藏
页码:1007 / +
页数:30
相关论文
共 227 条
  • [1] Structure and function of the type 1 insulin-like growth factor receptor
    Adams, TE
    Epa, VC
    Garrett, TPJ
    Ward, CW
    [J]. CELLULAR AND MOLECULAR LIFE SCIENCES, 2000, 57 (07) : 1050 - 1093
  • [2] Akiyama M, 2002, CANCER RES, V62, P3876
  • [3] Farnesyltransferase inhibitor tipifarnib is well tolerated, induces stabilization of disease, and inhibits farnesylation and oncogenic/tumor survival pathways in patients with advanced multiple myeloma
    Alsina, M
    Fonseca, R
    Wilson, EF
    Belle, AN
    Gerbino, E
    Price-Troska, T
    Overton, RM
    Ahmann, G
    Bruzek, LM
    Adjei, AA
    Kaufmann, SH
    Wright, JJ
    Sullivan, D
    Djulbegovic, B
    Cantor, AB
    Greipp, PR
    Dalton, WS
    Sebti, SM
    [J]. BLOOD, 2004, 103 (09) : 3271 - 3277
  • [4] Anderson K, 1999, SEMIN ONCOL, V26, P10
  • [5] Anderson KC, 2005, ONCOLOGY-NY, V19, P983
  • [6] Moving disease biology from the lab to the clinic
    Anderson, KC
    [J]. CANCER, 2003, 97 (03) : 796 - 801
  • [7] In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates
    Aparicio, A
    Gardner, A
    Tu, Y
    Savage, A
    Berenson, J
    Lichtenstein, A
    [J]. LEUKEMIA, 1998, 12 (02) : 220 - 229
  • [8] Aetiology of bone disease and the role of bisphosphonates in multiple myeloma
    Ashcroft, AJ
    Davies, FE
    Morgan, GJ
    [J]. LANCET ONCOLOGY, 2003, 4 (05) : 284 - 292
  • [9] Asosingh K, 2003, Verh K Acad Geneeskd Belg, V65, P127
  • [10] In vivo homing and differentiation characteristics of mature (CD45-) and immature (CD45+) 5T multiple myeloma cells
    Asosingh, K
    De Raeve, H
    Croucher, P
    Goes, E
    Van Riet, I
    Van Camp, B
    Vanderkerken, K
    [J]. EXPERIMENTAL HEMATOLOGY, 2001, 29 (01) : 77 - 84